Phase 2 N=27 Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects (THYMON-11001)
HIV Infections
Primary: Anti-Tat Antibody Titer — 698; 4 ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=85 An Observational, Retrospective, Multicenter, National Study for the Monitoring of Subjects Who Participated in the LoadET Clinical Trial
Ankylosing Spondylitis
Primary: Percentage of Participants Who Discontinued Treatment With Etanercept — 41.2 percentage of participants
Phase 2 N=146 Dose-Tolerability Titration Study to Evaluate The Efficacy And Safety Of Perampanel (E2007) In Patients With Post-Herpetic Neuralgia (PHN)
Neuralgia
Primary: Change From Baseline in Average Pain Scores to Week 15/ End of Treatment (EOT) (Including Modified BOCF Data) — -0.55; -1.30; -0.95; -0.50 Scores on a scale
Phase 3 N=6 Safety and Efficacy of Fluoxetine in Juvenile Fibromyalgia
Juvenile Primary Fibromyalgia Syndrome (JPFS) · Fibromyalgia
Primary: Average Pain Severity Score — 62 mm
N/A N=62 Neuroimaging Decision Making and Response Inhibition During Smoking Abstinence
Smoking
Primary: Signal Change in Functional Magnetic Resonance Imaging (fMRI) BOLD Signal Between Response Inhibition Trials and Control Trials in Right Inferior Frontal Cortex (rIFC)…
Phase 4 N=239 Superiority Study for Pain Treatment After Cesarean
Pain
Primary: Difference of Pain Scores on the Visual Analog Scale — 5.88; 4.85 VAS score at 24 hours — p=<0.05
N/A N=18 Open Label Study of Alefacept Injections to Patients With Moderate to Severe Psoriasis
Moderate to Severe Psoriasis
Primary: Number of Participants With Either or Both Intralesional Response and Systemic Response — 8; 0; 0; 6 Participants — p=0.0003
Phase 4 N=820 Smokers' Health Project: Self-Determination and Maintaining Tobacco Abstinence
Tobacco Use Disorder
Primary: 12 Month Prolonged Abstinence From Tobacco Measured at 12 Months From Completion of Intervention. — 169; 321; 318 participants
N/A N=530 School-based Asthma Therapy: Stage 2 Effectiveness Study
Asthma
Primary: Number of Symptom Free Days — 10.7; 11.6 Days
Phase 2 N=60 Treatment of Head & Neck Cancer With Chemotherapy and Radiation
Head and Neck Cancer
Primary: Two-Year Progression Free Survival (PFS) Probability, the Percentage of Patients Estimated to be Alive Without Worsening of Their Disease Two Years After Beginning…
Phase 2 N=20 Transcranial Magnetic Stimulation (TMS) for Individuals With Tourette's Syndrome
Tourette Syndrome
Primary: Yale Global Tic Severity Scale (Y-GTSS) — 29.5; 31.5 units on a scale
Phase 4 N=154 Clinical Evaluation of Iron Treatment Efficiency Among Non-anemic But Iron-deficient Female Blood Donors
Fatigue · Iron Deficiency
Primary: Level of Fatigue Before and After Iron Treatment/Placebo, Using a 10 Point Visual Analogue Scale. — 3.4; 3.5 centimeter — p=0.69
N/A N=293 The Long-term Value of Preoperative Duplex Before Surgery for Varicose Veins
Varicose Veins
Primary: Rate of Re-do Surgery — 15; 38 legs
Phase 2 N=140 Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Extensive Stage Small Cell Lung Cancer
Primary: Proportion of Patients With Objective Response by Solid Tumor Response Criteria (RECIST) — 0.697; 0.576 proportion of participants
Phase 4 N=300 Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging
Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson
Primary: Diarrhea (as Reported by the Patient) — 9; 26 participants — p=0.002